
STIFEL 2026: Oruka's IL-23p19 is showing strong efficacy in phase 2 studies compared to existing products and could be dosed as little as once or twice a year - a key update will read next month
CEO Lawrence Klein describes the data that has been seen so far (clearance in the 60% range at 16 weeks) and previews with upcoming 52 week data that will be coming in December. Plus, how the company is thinking about phase 3 design, and other assets in the pipeline.
Publisher
BiotechTV - News
Link
podcasters.spotify.com/pod/show/biotechtv4/episodes/STIFEL-2026-Orukas-IL-23p19-is-showing-strong-efficacy-in-phase-2-studies-compared-to-existing-products-and-could-be-dosed-as-little-as-once-or-twice-a-year---a-key-update-will-read-next-month-e3s87tb
Published
November 12, 2026
Duration
11 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
Host
BiotechTV
BiotechTV - News
@biotechtvnews
#showingstrongefficacy #studiescompared #existingproducts #lifesciences
